First Time Loading...

Roche Holding AG
SIX:ROG

Watchlist Manager
Roche Holding AG Logo
Roche Holding AG
SIX:ROG
Watchlist
Price: 288.8 CHF -0.65% Market Closed
Updated: May 31, 2023

Intrinsic Value

Roche Holding AG operates as a research healthcare company. [ Read More ]

The intrinsic value of one ROG stock under the Base Case scenario is 295.2 CHF. Compared to the current market price of 288.8 CHF, Roche Holding AG is Undervalued by 2%.

Key Points:
ROG Intrinsic Value
Base Case
295.2 CHF
Undervaluation 2%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

Financials

Balance Sheet Decomposition
Roche Holding AG

Current Assets 33.8B
Cash & Short-Term Investments 9.8B
Receivables 11.9B
Other Current Assets 12.1B
Non-Current Assets 54.3B
PP&E 24.2B
Intangibles 20.5B
Other Non-Current Assets 9.6B
Current Liabilities 27.2B
Accounts Payable 4.6B
Short-Term Debt 2.2B
Other Current Liabilities 20.5B
Non-Current Liabilities 32.9B
Long-Term Debt 21.4B
Other Non-Current Liabilities 11.5B
Efficiency
Fundamental Scores

ROG Profitability Score
Profitability Due Diligence

Roche Holding AG's profitability score is 73/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Free Cash Flow
Positive Gross Profit
Exceptional ROE
73/100
Profitability
Score

Roche Holding AG's profitability score is 73/100. The higher the profitability score, the more profitable the company is.

ROG Solvency Score
Solvency Due Diligence

Roche Holding AG's solvency score is 70/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Low D/E
Long-Term Solvency
70/100
Solvency
Score

Roche Holding AG's solvency score is 70/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ROG Price Targets Summary
Roche Holding AG

Wall Street analysts forecast ROG stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ROG is 319.15 CHF with a low forecast of 252.5 CHF and a high forecast of 399 CHF.

Lowest
Price Target
252.5 CHF
13% Downside
Average
Price Target
319.15 CHF
11% Upside
Highest
Price Target
399 CHF
38% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

ROG Competitors
Roche Holding AG

ROG Suppliers & Customers
Roche Holding AG

There is no information about
Roche Holding AG
key suppliers
Customers Map

Shareholder Return

ROG Return Decomposition
Main factors of price return

Market capitalization of ROG shares increased by 49.57% over the past 5 years. The primary factor behind the change was an increase in P/E multiple from 14.7 to 18.6, leading to a growth in the market capitalization of Roche Holding AG by 28.47%.

Market capitalization of ROG shares increased by 49.57% over the past 5 years. The primary factor behind the change was an increase in P/E multiple from 14.7 to 18.6, leading to a growth in the market capitalization of Roche Holding AG by 28.47%.

+49.57%
154B 231B
Market Cap Growth
+28.47%
14.7 18.6
P/E Change
+21.1%
10.5B 12.4B
Earnings Growth
Market Cap Growth
+49.57%
P/E Change
+28.47%
Earnings Growth
+21.1%
What is price return decomposition?

ROG Price
Roche Holding AG

1M 1M
+3%
6M 6M
-3%
1Y 1Y
-8%
3Y 3Y
-5%
5Y 5Y
+60%
10Y 10Y
+66%
Annual Price Range
288.8
52w Low
254.2109
52w High
321.8012
Price Metrics
Average Annual Return 19.03%
Standard Deviation of Annual Returns 13.08%
Max Drawdown -34%
Shares Statistics
Market Capitalization 231B CHF
Shares Outstanding 800 579 145
Percentage of Shares Shorted
N/A

Company Profile

Roche Holding AG Logo
Roche Holding AG

Country

Switzerland

Industry

Pharmaceuticals

Market Cap

231B CHF

Dividend Yield

0%

Description

Roche Holding AG operates as a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 100,920 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Contact

BASEL-STADT
Basel
Grenzacherstr. 124

IPO

2001-05-04

Employees

100 920

Officers

CEO & Exec. Director
Dr. Severin Schwan Ph.D.
Chief Financial & Information Officer
Dr. Alan Hippe
Chief People Officer
Ms. Cristina A. Wilbur
Head of Roche Pharma Research & Early Devel.
Dr. Johannes Carolus Clevers M.D., Ph.D.
Chief Exec. Officer of Roche Diagnostics
Dr. Thomas Schinecker
Chief Exec. Officer of Roche Pharmaceuticals
Mr. William N. Anderson
Show More
Head of Investor Relations
Dr. Bruno Eschli
Gen. Counsel
Ms. Claudia Bockstiegel
Chief Compliance Officer
Ms. Pascale Schmidt
Head of Group Communications
Ms. Barbara Schadler
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one ROG stock?

The intrinsic value of one ROG stock under the Base Case scenario is 295.2 CHF.

Is ROG stock undervalued or overvalued?

Compared to the current market price of 288.8 CHF, Roche Holding AG is Undervalued by 2%.